163 related articles for article (PubMed ID: 24888812)
1. Complete Response of Metastatic Androgen Receptor-Positive Breast Cancer to Bicalutamide: Case Report and Review of the Literature.
Arce-Salinas C; Riesco-Martinez MC; Hanna W; Bedard P; Warner E
J Clin Oncol; 2016 Feb; 34(4):e21-4. PubMed ID: 24888812
[No Abstract] [Full Text] [Related]
2. Phase II trial of bicalutamide in patients with androgen receptor-positive, estrogen receptor-negative metastatic Breast Cancer.
Gucalp A; Tolaney S; Isakoff SJ; Ingle JN; Liu MC; Carey LA; Blackwell K; Rugo H; Nabell L; Forero A; Stearns V; Doane AS; Danso M; Moynahan ME; Momen LF; Gonzalez JM; Akhtar A; Giri DD; Patil S; Feigin KN; Hudis CA; Traina TA;
Clin Cancer Res; 2013 Oct; 19(19):5505-12. PubMed ID: 23965901
[TBL] [Abstract][Full Text] [Related]
3. [Bicalutamide].
Taéron C
Rev Infirm; 2010 Mar; (158):47-9. PubMed ID: 20383962
[No Abstract] [Full Text] [Related]
4. A dramatic, objective antiandrogen withdrawal response: case report and review of the literature.
Lau YK; Chadha MK; Litwin A; Trump DL
J Hematol Oncol; 2008 Nov; 1():21. PubMed ID: 18986533
[TBL] [Abstract][Full Text] [Related]
5. Salvage therapy with bicalutamide 150 mg in nonmetastatic castration-resistant prostate cancer.
Lodde M; Lacombe L; Fradet Y
Urology; 2010 Nov; 76(5):1189-93. PubMed ID: 20303155
[TBL] [Abstract][Full Text] [Related]
6. Serial [
Boers J; Venema CM; de Vries EFJ; Hospers GAP; Boersma HH; Rikhof B; Dorbritz C; Glaudemans AWJM; Schröder CP
Eur J Cancer; 2021 Feb; 144():151-161. PubMed ID: 33341447
[TBL] [Abstract][Full Text] [Related]
7. [Bicalutamide].
Kotake T
Nihon Rinsho; 2000 Jul; 58 Suppl():216-22. PubMed ID: 11022717
[No Abstract] [Full Text] [Related]
8. Primary signet-ring cell/histiocytoid carcinoma of the eyelid expressing androgen receptors and treated with bicalutamide.
Sakamoto K; Ito T; Tanioka F; Fukamizu H; Tokura Y
J Dermatol; 2017 Sep; 44(9):e230-e231. PubMed ID: 28543368
[No Abstract] [Full Text] [Related]
9. Excellent Response With Alpelisib and Bicalutamide for Advanced Salivary Duct Carcinoma With PIK3CA Mutation and High Androgen Receptor Expression-A Case Report.
Sheth H; Kumar P; Shreenivas A; Sambath J; Pragya R; Madre C; Athikari N; Khandare H; Peshattiwar V; Datar R; Limaye S
JCO Precis Oncol; 2021; 5():. PubMed ID: 34036229
[No Abstract] [Full Text] [Related]
10. Bicalutamide with radiotherapy for prostate cancer.
Brower V
Lancet Oncol; 2017 Mar; 18(3):e141. PubMed ID: 28190764
[No Abstract] [Full Text] [Related]
11. A randomised, double-blind study comparing the addition of bicalutamide with or without dutasteride to GnRH analogue therapy in men with non-metastatic castrate-resistant prostate cancer.
Chu FM; Sartor O; Gomella L; Rudo T; Somerville MC; Hereghty B; Manyak MJ
Eur J Cancer; 2015 Aug; 51(12):1555-69. PubMed ID: 26048455
[TBL] [Abstract][Full Text] [Related]
12. Editorial comment to Japan Cancer of the Prostate Risk Assessment for combined androgen blockade including bicalutamide: clinical application and validation.
Yoshida T
Int J Urol; 2013 Jul; 20(7):714-5. PubMed ID: 23216631
[No Abstract] [Full Text] [Related]
13. [Incorrect about hormone treatment in prostatic cancer].
Fosså SD; Egey A; Haukaas SA; Angelsen A; Klepp O; Berge V; Axcrona K; Lilleby W
Tidsskr Nor Laegeforen; 2009 Feb; 129(5):429. PubMed ID: 19247406
[No Abstract] [Full Text] [Related]
14. Oral bicalutamide for female pattern hair loss: A pilot study.
Fernandez-Nieto D; Saceda-Corralo D; Rodrigues-Barata R; Hermosa-Gelbard A; Moreno-Arrones O; Jimenez-Cauhe J; Ortega-Quijano D; Vano-Galvan S
Dermatol Ther; 2019 Nov; 32(6):e13096. PubMed ID: 31579984
[No Abstract] [Full Text] [Related]
15. Androgen deprivation and androgen receptor competition by bicalutamide induce autophagy of hormone-resistant prostate cancer cells and confer resistance to apoptosis.
Boutin B; Tajeddine N; Vandersmissen P; Zanou N; Van Schoor M; Mondin L; Courtoy PJ; Tombal B; Gailly P
Prostate; 2013 Jul; 73(10):1090-102. PubMed ID: 23532738
[TBL] [Abstract][Full Text] [Related]
16. [Unreliable survival analysis].
Tretli S; Kvåle R; Hernes E
Tidsskr Nor Laegeforen; 2009 Feb; 129(5):429-30; author reply 430. PubMed ID: 19247405
[No Abstract] [Full Text] [Related]
17. Photosensitive drug eruption induced by bicalutamide within the UVB action spectrum.
Sasada K; Sakabe J; Tamura A; Kasuya A; Shimauchi T; Ito T; Hirakawa S; Tokura Y
Eur J Dermatol; 2012; 22(3):402-3. PubMed ID: 22503957
[No Abstract] [Full Text] [Related]
18. The third analysis of the bicalutamide Early Prostate Cancer programme.
Iversen P;
BJU Int; 2006 Mar; 97(3):438-9. PubMed ID: 16469002
[No Abstract] [Full Text] [Related]
19. Androgen receptor-positive salivary duct carcinoma: a disease entity with promising new treatment options.
Jaspers HC; Verbist BM; Schoffelen R; Mattijssen V; Slootweg PJ; van der Graaf WT; van Herpen CM
J Clin Oncol; 2011 Jun; 29(16):e473-6. PubMed ID: 21422415
[No Abstract] [Full Text] [Related]
20. [The use of Casodex (bicalutamide) in the treatment of disseminated prostatic cancer].
Sivko AV; Prokhorov AV
Urol Nefrol (Mosk); 1997; (3):49-52. PubMed ID: 9245060
[No Abstract] [Full Text] [Related]
[Next] [New Search]
